In summary, accumulated evidence validated various gene expression disorders or mutations in NSCLC cells impair the activity, tumor-cell-killing function, proliferation, and infiltration of CD8+ T-cells in TME, which contribute to exhausted CD8+ T-cells for immunotherapy resistance (91, 97, 111, 116–118). This evidence concerns the gene CD8A and non-small cell lung carcinoma.